We recently spoke with Eric Le Royer, CEO of Geneva-based Endosense, about how his company applied MEMS technology to the development of a new catheter to improve the procedures for treating atrial fibrillation. According to Mr. Le Royer, atrial fibrillation is today’s most prevalent cardiac rhythm disorder and is estimated to affect more than 6 million people worldwide. Of these, approximately 2.6 million cases have been treated by three types of therapy – 2.5 million with drugs, 60,000 with surgery and 70,000 with conventional catheter ablation. The catheter market for treating atrial cardiac disorder is expected to grow from $500 million today at a rate of 20% per annum and reach $1.25 billion in 2015.
Continue reading "MEMS application for treating cardiac rhythm disorder" »